TBB is a cell-permeable, selective inhibitor of casein kinase-2 (CK2) (IC50 = 0.9 and 1.6 μM for rat liver and human recombinant CK2 respectively). Exhibits modest discrimination between CK2 subunits, with Ki values ranging from 80 nM to 210 nM. Acts in an ATP/GTP-competitive manner and displays one to two orders of magnitude selectivity over a panel of 33 protein kinases.
动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数 | |
例如,已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法:将88 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到该药物用于大鼠的等效剂量44 mg/kg。
[1] Sarno, S., et al., 2001. Selectivity of 4,5,6,7-tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 ('casein kinase-2'). FEBS letters. 496(1): 44-8. PMID: 11343704
[2] Borowski, Peter., et al., 2003. Halogenated benzimidazoles and benzotriazoles as inhibitors of the NTPase/helicase activities of hepatitis C and related viruses. European journal of biochemistry / FEBS. 270(8): 1645-53. PMID: 12694177
[3] Sarno, Stefania., et al., 2003. Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA). The Biochemical journal. 374(Pt 3): 639-46. PMID: 12816539
[4] Duncan, James S., et al., 2008. An unbiased evaluation of CK2 inhibitors by chemoproteomics: characterization of inhibitor effects on CK2 and identification of novel inhibitor targets. Molecular & cellular proteomics : MCP. 7(6): 1077-88. PMID: 18258654
[5] Fromageot, H P., et al., 1977. Adsorption of human erythrocyte surface glycoprotein onto polystyrene latex spheres. The Journal of laboratory and clinical medicine. 90(2): 324-9. PMID: 886218
[6] Ruzzene, Maria., et al., 2002. Protein kinase CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB) induces apoptosis and caspase-dependent degradation of haematopoietic lineage cell-specific protein 1 (HS1) in Jurkat cells. The Biochemical journal. 364(Pt 1): 41-7. PMID: 11988074
分子式 C6HBr4N3 |
分子量 434.71 |
CAS号 17374-26-4 |
储存方式 ﹣20 ℃冷藏长期储存。冰袋运输 |
溶剂(常温) |
DMSO 100 mM |
Water <1 mg/mL |
Ethanol 15 mM |
体内溶解度
NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
NCT02401347 | Advanced Breast Cancer|HER2/Neu Negative|Triple-Negative Breast Cancer | Drug: Talazoparib Tosylate | Melinda Telli|National Cancer Institute (NCI)|Stanford University | Phase 2 | 2015-08-01 | 2015-08-09 |
NCT02484066 | Lung Cancer | Device: VBN (DirectPath; Olympus)|Device: EBUS-GS (Olympus)|Device: X-ray | Jiayuan Sun|National Cancer Center, Japan|Shanghai Chest Hospital | 2015-06-01 | 2015-06-26 | |
NCT01704547 | Breast Cancer | University of Maryland | 2012-10-01 | 2016-12-05 | ||
NCT00626587 | Peripheral Pulmonary Lesions | Device: Olympus NA-2C-1 Transbronchial needle aspiration (TBNA) | Chang Gung Memorial Hospital | 2005-01-01 | 2008-02-28 | |
NCT01748279 | COPD | Drug: Atorvastatin|Drug: Formoterol|Drug: Lactose tablet | Medical University of Bialystok | Phase 4 | 2012-12-01 | 2013-04-21 |
NCT01894113 | Interstitial Lung Disease | Procedure: transbronchial lung biopsy | University Hospital Tuebingen | 2012-01-01 | 2015-05-02 | |
NCT00888212 | Sarcoidosis | Procedure: Bronchoscopy | University Hospital, Ghent | 2008-06-01 | 2009-06-19 | |
NCT01785433 | COPD | Drug: Tiotropium HFA BAI 4.5 mcg|Drug: Tiotropium HFA BAI 9.0 mcg|Drug: SPIRIVAHandiHaler 18 mcg/day|Drug: Spiriva Respimat5 mcg/day | Teva Pharmaceutical Industries | Phase 1|Phase 2 | 2013-01-01 | 2014-08-07 |
NCT02203474 | Chronic Obstructive Pulmonary Disease|COPD | Drug: Tiotropium HFA BAI 5 mcg|Drug: Tiotropium 18 mcg Capsule|Drug: Placebo | Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries | Phase 2 | 2014-08-01 | 2014-08-26 |
NCT01011543 | Pulmonary Tuberculosis | Procedure: Diagnostic techniques in pulmonary tuberculosis | Centre Hospitalier Universitaire Saint Pierre | 2009-08-01 | 2015-08-07 |
注:以上所有数据均来自公开文献,并不保证对所有实验均有效,数据仅供参考。
相关化合物库
使用AMQUAR产品发表文献后请联系我们